![]() |
Open for inclusion |
Biomarker driven and dose intensified chemoimmunotherapy with early CNS prophylaxis in patients less than 65 years with high risk diffuse large B-cell lymphpomaCancer type: Lymphoma Phase: II Principal Investigator: Leppä Sirpa Country: FI Keywords: Finland, Helsinki Status: Open for inclusion Link to Clinicaltrials.gov: https://clinicaltrials.gov/ct2/show/NCT03293173 |